KRAS and neoplasm: No additional KRAS mutations were detected by ddPCR and the detection rate of tumor-specific mutations in samples, where both MassARRAY and ddPCR analyses were done, was higher with the MassARRAY technique (10/19, 52.6% for iPLEX, 14/19, 73.7% for UHS) than with ddPCR (8/19, 42.1%) (Table G in S1 File).